Clinical impact and relevance of antibiotic resistance

Advanced Drug Delivery Reviews

Volumn 57, Issue 10, 2005, Pages 1514-1527

  French, G L ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Antimicrobial resistance; Healthcare costs; Treatment; Treatment outcomes

Indexed keywords

BACTERIA; COST EFFECTIVENESS; HEALTH CARE; HOSPITALS; MICROBIOLOGY; PATIENT TREATMENT;

ANTIMICROBIAL RESISTANCE; EMPIRICAL THERAPY; MORTALITY RATE;

ANTIBIOTICS;

AMIKACIN; AMINOGLYCOSIDE; AMOXICILLIN; ANTIBIOTIC AGENT; BETA LACTAM DERIVATIVE; CARBAPENEM DERIVATIVE; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COTRIMOXAZOLE; FLUCLOXACILLIN; GENTAMICIN; GLYCOPEPTIDE; LINEZOLID; MEROPENEM; OXAZOLIDINONE DERIVATIVE; PENICILLIN DERIVATIVE; PENICILLIN G; PENICILLIN V; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE DERIVATIVE; TEICOPLANIN; TRIMETHOPRIM; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTEREMIA; BACTERIAL INFECTION; BACTERIAL MENINGITIS; COST EFFECTIVENESS ANALYSIS; CROSS INFECTION; DOSE RESPONSE; DRUG COST; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG USE; ENTEROBACTERIACEAE; ENTEROCOCCUS; FAMILY COUNSELING; HEALTH CARE COST; HEALTH CARE DELIVERY; HOSPITAL BED; HOSPITAL CARE; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; LOBAR PNEUMONIA; MORTALITY; PATIENT CARE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; SIDE EFFECT; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; TOXICITY; TREATMENT FAILURE; TREATMENT OUTCOME; URINARY TRACT INFECTION;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; COST OF ILLNESS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HEALTH CARE COSTS; HUMANS; TREATMENT OUTCOME;

EID: 22144462417     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2005.04.005     Document Type: Review

References (92)

1. M. Finland, W.F. Jones, and M.W. Barnes Occurrence of serious bacterial infections since introduction of antibacterial agents JAMA 170 1959 2188 2197
2. M.L. Cohen Epidemiology of drug resistance implications for a post-antimicrobial era Science 257 1992 1050 1055
3. H.C. Neu The crisis in antibiotic resistance Science 257 1992 1064 1072
4. C.M. Kunin Resistance to antimicrobial drugs - a worldwide calamity Ann. Intern. Med. 118 1993 557 561
5. S.D. Holmberg, S.L. Solomon, and P.A. Blake Health and economic impacts of antimicrobial resistance Rev. Infect. Dis. 9 1987 1065 1078
6. M.S. Niederman Impact of antibiotic resistance on clinical outcomes and the cost of care Crit. Care Med. 29 4 Suppl. 2001 N114 N120
7. S.E. Cosgrove, and Y. Carmeli The impact of antimicrobial resistance on health and economic outcomes Clin. Infect. Dis. 36 2003 1433 1437
8. J.E. McGowan Economic impact of antimicrobial resistance Emerg. Infect. Dis. 7 2001 292 296
9. M.E. Singer, I. Harding, M.R. Jacobs, and D.H. Jaffe Impact of antimicrobial resistance on health outcomes in the out-patient treatment of adult community-acquired pneumonia a probability model J. Antimicrob. Chemother. 51 2003 1269 1282
10. R. Plowman, N. Graves, M. Griffin, J.A. Roberts, A.V. Swan, B.D. Cookson, and L. Taylor Socio-Economic Burden of Hospital Acquired Infection 1999 PHLS London
11. R.A. Cox, C. Conquest, C. Mallaghan, and R.R. Marples A major outbreak of methicillin-resistant Staphylococcus aureus caused by a new phage-type (EMRSA-16) J. Hosp. Infect. 29 1995 87 106
12. S. Mehtar How to cost and fund an infection control programme J. Hosp. Infect. 25 1993 57 69
13. K.K. Lai, A.L. Kelley, and Z.S. Melvin Failure to eradicate vancomycin-resistant enterococci in a university hospital and the cost of barrier precautions Infect. Control Hosp. Epidemiol. 19 1998 647 652
14. T. Kim, P.I. Oh, and A.E. Simor The economic impact of methicillin-resistant Staphylococcus aureus in Canadian hospitals Infect. Control Hosp. Epidemiol. 22 2001 99 104
15. E.A. Bryce, S.M. Tiffin, J.L. Isaac-Renton, and C.J. Wright Evidence of delays in transferring patients with methicillin-resistant Staphylococcus aureus or vancomycin-resistant Enterococcus to long-term-care facilities Infect. Control Hosp. Epidemiol. 21 2000 270 271
16. M.H. Kollef Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients Clin. Infect. Dis. 31 2000 S131 S138
17. C.S. Bryan, K.L. Reynolds, and E.R. Brenner Analysis of 1186 episodes of Gram-negative bacteremia in non-university hospitals: the effects of antimicrobial therapy Rev. Infect. Dis. 5 1983 629 638
18. C.M. Luna, D. Blanzaco, and M.S. Niederman Resolution of ventilator-associated pneumonia prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome Crit. Care Med. 31 2003 676 682
19. J. Rello, M. Gallego, and D. Mariscal The value of routine microbial investigation in ventilator-associated pneumonia Am. J. Respir. Crit. Care Med. 156 1997 196 200
20. L. Leibovici, I. Shraga, and M. Drucker The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection J. Intern. Med. 244 1998 379 386
21. M.P. Weinstein, M.L. Towns, and S.M. Quartey The clinical significance of positive blood cultures in the 1990s a prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults Clin. Infect. Dis. 24 1997 584 602
22. E.H. Ibrahim, G. Sherman, and S. Ward The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in ICU setting Chest 118 2000 146 155
23. T.P. Meehan, M.J. Fine, and H.M. Krumholz Quality of care, process, and outcomes in elderly patients with pneumonia JAMA 278 1997 2080 2084
24. N.C. Dean, M.P. Silver, and K.A. Bateman Decreased mortality after implementation of a treatment guideline for community-acquired pneumonia Am. J. Med. 110 2002 451 457
25. M. Iregui, S. Ward, and G. Sherman Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia Chest 122 2002 262 268
26. J.L. Trovillet, J. Chastre, and A. Vuagnat Ventilator-associated pneumonia caused by potentially drug-resistant bacteria Am. J. Respir. Crit. Care Med. 57 1998 1531 1539
27. M.H. Kollef, and V.J. Fraser Antibiotic resistance in the intensive care unit Ann. Intern. Med. 134 2001 298 314
28. S.K. Fridkin Increasing prevalence of antimicrobial resistance in intensive care units Crit. Care Med. 29 2001 N64 N68 (Suppl.)
29. M.H. Kollef Treatment of ventilator-associated pneumonia: get it right from the start Crit. Care Med. 31 2003 969 970
30. M.H. Kollef, G. Sherman, S. Ward, and V.J. Fraser Inadequate antimicrobial treatment of infections a risk factor for hospital mortality among critically ill patients Chest 115 1999 462 474
31. N. Singh, P. Rogers, and C.W. Atwood Short course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription Am. J. Respir. Crit. Care Med. 162 2000 505 511
32. M.H. Kollef Hospital-acquired pneumonia and de-escalation of antimicrobial treatment Crit. Care Med. 29 2001 1473 1475
33. M. Chomarat Resistance of bacteria in urinary tract infections Int. J. Antimicrob. Agents 16 2004 483 487
34. A.M. Sefton The impact of resistance on the management of urinary tract infections Int. J. Antimicrob. Agents 16 2004 489 491
35. K. Gupta, T.M. Hooton, and W.E. Stamm Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections Ann. Intern. Med. 135 2001 41 50
36. P.J. Wu, K. Shannon, and I. Phillips β-Lactamases and susceptibility to β-lactam antibiotics in Escherichia coli J. Antimicrob. Chemother. 30 1992 868 871
37. P. Stapleton, P.-J. Wu, and A. King Incidence and mechanisms of resistance to the combination of amoxicillin and clavulanic acid in Escherichia coli Antimicrob. Agents Chemother. 39 1995 2478 2483
38. A. Philippon, R. Labia, and G. Jacoby Extended-spectrum β-lactamases Antimicrob. Agents Chemother. 33 1989 1131 1136
39. G.A. Jacoby, and G.L. Archer New mechanisms of bacterial resistance to antimicrobial agents New Engl. J. Med. 324 1991 601 612
40. K.P. Shannon, and G.L. French Increasing resistance to antimicrobial agents of Gram-negative organisms isolated at a London teaching hospital, 1995-2000 J. Antimicrob. Chemother. 53 2004 818 825
41. M. Leung, K. Shannon, and G. French Rarity of transferable β-lactamase production by Klebsiella species J. Antimicrob. Chemother. 39 1997 737 745
42. G.L. French, K.P. Shannon, and N. Simmons Hospital outbreak of Klebsiella pneumoniae resistant to broad-spectrum cephalosporins and β-lactam-β- lactamase inhibitor combinations by hyperproduction of SHV-5 β-lactamase J. Clin. Microbiol. 34 1996 358 363
43. K. Shannon, K. Fung, and R. Anthony A hospital outbreak of extended-spectrum β-lactamase-producing Klebsiella pneumoniae investigated by RAPD typing and analysis of the genetics and mechanisms of resistance J. Hosp. Infect. 39 1998 291 300
44. K. Shannon, P. Stapleton, and X. Xiaoqin Extended-spectrum β-lactamase-producing Klebsiella pneumoniae strains causing nosocomial outbreaks of infection in the United Kingdom J. Clin. Microbiol. 36 1998 3105 3110
45. M.B. Macrae, K.P. Shannon, and D.M. Rayner A simultaneous outbreak on a neonatal unit of two strains of multiply antibiotic resistant Klebsiella pneumoniae controllable only by ward closure J. Hosp. Infect. 49 2001 183 192
46. M. Yuan, H. Aucken, and L.M. Hall Epidemiological typing of klebsiellae with extended-spectrum beta-lactamases from European intensive care units J. Antimicrob. Chemother. 41 1998 527 539
47. E. Lautenbach, J.B. Patel, and W.B. Bilker Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae risk factors for infection and impact of resistance on outcomes Clin. Infect. Dis. 32 2001 1162 1171
48. B. Du, Y. Long, and H. Liu Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection risk factors and clinical outcome Intensive Care Med. 28 2002 1718 1723
49. Y.K. Kim, H. Pai, and H.J. Lee Bloodstream infections by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children epidemiology and clinical outcome Antimicrob. Agents Chemother. 46 2002 1481 1491
50. A. Pena, M. Pujol, and C. Ardanuy An outbreak of hospital-acquired Klebsiella pneumoniae bacteraemia, including strains producing extended-spectrum beta-lactamase J. Hosp. Infect. 47 2001 53 59
51. J.W. Chow, M.J. Fine, and D.M. Shlaes Enterobacter bacteremia clinical features and emergence of antibiotic resistance during therapy Ann. Intern. Med. 115 1991 585 590
52. K.S. Kaye, S. Cosgrove, and A. Harris Risk factors for emergence of resistance to broad spectrum cephalosporins among Enterobacter species Antimicrob. Agents Chemother. 45 2001 2628 2630
53. S.E. Cosgrove, K.S. Kaye, G.M. Eliopoulos, and Y. Carmeli Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species Arch. Intern. Med. 162 2002 185 190
54. Y. Carmelli, N. Troilett, A.W. Karchmer, and M.H. Samore Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa Arch. Intern. Med. 159 1999 1127 1132
55. M. Hilf, V.L. Yu, and J. Sharp Antibiotic therapy for Pseudomonas aeruginosa bacteraemia outcome correlations in a prospective study of 200 patients Am. J. Med. 87 1989 540 546
56. G. Grisaru-Soen, L. Lerner-Geva, and N. Keller Pseudomonas aeruginosa bacteremia in children analysis of trends in prevalence, antibiotic resistance and prognostic factors Pediatr. Infect. Dis. J. 19 2000 959 963
57. J.A. Paladino, J.L. Sunderlin1, A. Forrest, and J.J. Schentag Characterization of the onset and consequences of pneumonia due to fluoroquinolone-susceptible or -resistant Pseudomonas aeruginosa J. Antimicrob. Chemother. 52 1999 457 463
58. D.C. Shanson Antibiotic resistance in Staphylococcus aureus J. Hosp. Infect. 2 1981 11 36
59. W. Brumfitt, and J. Hamilton-Miller Methicillin-resistant Staphylococcus aureus N. Engl. J. Med. 320 1989 1188 1196
60. NNIS (National Nosocomial Infections Surveillance) System Report, data summary from January 1992 to June 2002, issued August 2002 Am. J. Infect. Control 30 2002 458 475
61. EARSS (The European Antimicrobial Resistance Surveillance System) Annual Report (2001).
62. G.L. French, A.F.B. Cheng, and J.M.L. Ling Hong Kong strains of methicillin-resistant and methicillin-sensitive Staphylococcus aureus have similar virulence J. Hosp. Infect. 15 1990 117 125
63. M. Michel, and L. Gutmann Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci therapeutic realities and possibilities Lancet 349 1997 1901 1906
64. J. May, K. Shannon, A. King, and G.L. French Glycopeptide tolerance in Staphylococcus aureus J. Antimicrob. Chemother. 42 1998 189 197
65. C. Liu, and H.F. Chambers Staphylococcus aureus with heterogeneous resistance to vancomycin epidemiology, clinical significance, and critical assessment of diagnostic methods Antimicrob. Agents Chemother. 47 2004 3040 3045
66. Centers for Disease Control and Prevention (CDC) Vancomycin-resistant Staphylococcus aureus-New York, 2004 MMWR 53 2004 322 323
67. S.E. Cosgrove, G. Sakoulas, and E.N. Perencevich Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis Clin. Infect. Dis. 36 2003 53 59
68. J.J. Engemann, Y. Carmeli, and S.E. Cosgrove Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection Clin. Infect. Dis. 36 2003 592 598
69. R.G. Wunderink, J. Rello, and S.K. Cammarata Linezolid vs. vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia Chest 124 2003 1789 1797
70. M. Wilcox, D. Nathwani, and M. Dryden Linezolid compared with teicoplanin for the treatment of suspected or proven gram-positive infections J. Antimicrob. Chemother. 53 2004 335 344
71. R. Leclerq, and P. Courvalin Resistance to glycopeptides in enterococci Clin. Infect. Dis. 24 1997 545 556
72. J.E. Patterson, A.H. Sweeney, and M. Simms An analysis of 110 serious enterococcal infections. Epidemiology, antibiotic susceptibility, and outcome Medicine 74 1995 191 200
73. Stroud, J. Edwards, and L. Danzing Risk factors for mortality associated with enterococcal bloodstream infections Infect. Control Hosp. Epidemiol. 17 1996 576 580
74. M.B. Edmond, J.F. Ober, and J.D. Dawson Vancomycin-resistant enterococcal bacteremia natural history and attributable mortality Clin. Infect. Dis. 23 1996 1234 1239
75. P.K. Linden, A.W. Pasculle, and R. Manez Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium Clin. Infect. Dis. 22 1996 663 670
76. V. Stosor, L.R. Peterson, M. Postelnick, and G.A. Noskin Enterococcus faecium bacteremia Arch. Intern. Med. 158 1998 522 527
77. Y. Carmelli, G. Epiopoulos, E. Mozaffari, and M. Samore Health and economic outcomes of vancomycin-resistant enterococci Arch. Intern. Med. 162 2002 2223 2228
78. S.L. Kaplan, and E.O. Mason Management of infections due to antibiotic resistant Streptococcus pneumoniae Clin. Microbiol. Rev. 11 1998 628 644
79. J.P. Metlay, and D.E. Singer Outcomes in lower respiratory tract infections and the impact of antimicrobial drug resistance Clin. Microbiol. Infect. 8 Suppl. 2 2002 1 11
80. T.Q. Tan Antibiotic resistant infections due to Streptococcus pneumoniae impact on therapeutic options and clinical outcomes Curr. Opin. Infect. Dis. 16 2003 271 277
81. S.F. Dowell, R. Smith, and K. Leversedge Failure of treatment of pneumonia associated with highly resistant pneumococci in a child Clin. Infect. Dis. 29 1999 462 463
82. D.R. Feikin, A. Schuchat, and M. Kolczak Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997 Am. J. Public Health 90 2000 223 229
83. S.L. Kaplan, L. Sheldon, and E.O. Mason Six year multicentre surveillance of invasive pneumococcal infections in children Pediatr. Infect. Dis. J. 21 2002 141 147
84. G.S. Turett, S. Blum, and B.A. Fazel Penicillin-resistance and other predictors of mortality in pneumococcal bacteremia in a population with high human immunodeficiency virus seroprevalence Clin. Infect. Dis. 29 1999 321 327
85. K.P. Klugman, I.R. Friedland, and J.S. Bradley Bactericidal activity against cephalosporin-resistant Streptococcus pneumoniae in cerebrospinal fluid of children with acute bacterial meningitis Antimicrob. Agents Chemother. 39 1995 1988 1992
86. M. Arditi, E.O. Mason, and J.S. Bradley Three-year multicenter surveillance of pneumococcal meningitis in children clinical characteristics and outcome related to penicillin susceptibility and dexamethasone use Pediatrics 102 1998 1087 1097
87. A.E. Fiore, J.F. Moroney, and M.M. Farley Clinical outcomes of meningitis caused by Streptococcus pneumoniae in the era of antibiotic resistance Clin. Infect. Dis. 30 2000 71 77
88. S.C. Buckingham, J.A. Mccullers, and J. Lujan-Zilbermann Pneumococcal meningitis in children relationship of antibiotic resistance to clinical characteristics and outcomes Pediatr. Infect. Dis. J. 20 2001 837 843
89. J.S. Bradley, and W.M. Scheld The challenge of penicillin-resistant Streptococcus pneumoniae meningitis current antibiotic therapy in the 1990s Clin. Infect. Dis. 24 Suppl. 2 1997 S213 S221
90. Committee on Infectious Diseases of the American Academy of Pediatrics Therapy for children with invasive pneumococcal infections Pediatrics 99 1997 289 299
91. I.R. Friedland, and K.P. Klugman Failure of chloramphenicol therapy in penicillin-resistant pneumococcal meningitis Lancet 339 1992 405 408
92. D.A. Goldman, R.A. Weinstein, and R.P. Wenzel Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganism in hospitals a challenge to hospital leadership JAMA 275 1996 234 240